Effectiveness and costs of chemical versus electrical cardioversion of atrial fibrillation

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project

“…We assumed that after 8 hours, one extra bed-day would be incurred at a cost of £338 [the excess bed-day cost for an elective inpatient stay for Healthcare Resource Group (HRG) EB07I 109 ]. For comparison, a randomised trial of cardioversion 196 reported a mean length of stay of 1 day (SD = 2) for 72 patients randomised to an initial PCV strategy, and 2 days (SD = 2) for 67 randomised to initial ECV.…”

The Costs of Care in Atrial Fibrillation and the Effect of Treatment Modalities in Germany

“…Despite the high prevalence of AF, few studies have been performed to evaluate the overall cost of care for AF patients in clinical practice. The majority of the economic studies on AF estimate the costs of specific treatments such as ablation, anticoagulation, electrical cardioversion or several pharmacological treatments [9–13]. Studies examining the cost of disease in patients with AF have been conducted in the UK, France, and the USA [14–16] but because of differing health‐care and compensation systems, the transferability of national cost evaluations is limited.…”

Management of nonvalvular atrial fibrillation : A comprehensive approach

“…[23] No difference between the two types of cardioversions has been found regarding the efÞ cacy to restore sinus rhythm and other issues (i.e., incidence of thromboembolism and MANAGEMENT OF NONVALVULAR ATRIAL FIBRILLATION stroke). [20,24] As outlined by the current guidelines, [7] patients who have been in AF for less than 48 hours are eligible for early cardioversion, while patients who have been in AF for more than 48 hours should be considered for anticoagulation therapy and elective cardioversion. All the strategies require appropriate administration of antithrombotic therapy to reduce the risk of stroke and other thromboembolic events.…”